BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

322 related articles for article (PubMed ID: 33724354)

  • 1. Progressive Multifocal Leukoencephalopathy in a Patient With Progressive Multiple Sclerosis Treated With Ocrelizumab Monotherapy.
    Patel A; Sul J; Gordon ML; Steinklein J; Sanguinetti S; Pramanik B; Purohit D; Haroutunian V; Williamson A; Koralnik I; Harel A
    JAMA Neurol; 2021 Jun; 78(6):736-740. PubMed ID: 33724354
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Progressive multifocal leukoencephalopathy in a patient with relapsing multiple sclerosis treated with ocrelizumab: A case report.
    Puig-Casadevall M; Álvarez-Bravo G; Varela AQ; Robles-Cedeño R; Sànchez Cirera L; Miguela A; Laguillo G; Montalban X; Hauser SL; Ramió-Torrentà L
    Eur J Neurol; 2023 Oct; 30(10):3357-3361. PubMed ID: 37485841
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Ocrelizumab Treatment in Patients with Primary Progressive Multiple Sclerosis: Short-term Safety Results from a Compassionate Use Programme in Germany.
    Rauer S; Hoshi MM; Pul R; Wahl M; Schwab M; Haas J; Ellrichmann G; Krumbholz M; Tackenberg B; Saum KU; Buck F; Leemhuis J; Kretschmann A; Aktas O
    Clin Neurol Neurosurg; 2020 Oct; 197():106142. PubMed ID: 32920498
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Mild progressive multifocal leukoencephalopathy after switching from natalizumab to ocrelizumab.
    Toorop AA; van Lierop ZYG; Strijbis EEM; Teunissen CE; Petzold A; Wattjes MP; Barkhof F; de Jong BA; van Kempen ZLE; Killestein J
    Neurol Neuroimmunol Neuroinflamm; 2021 Jan; 8(1):. PubMed ID: 33051344
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Risk Assessment of Progressive Multifocal Leukoencephalopathy in Multiple Sclerosis Patients during 1 Year of Ocrelizumab Treatment.
    Prezioso C; Grimaldi A; Landi D; Nicoletti CG; Brazzini G; Piacentini F; Passerini S; Limongi D; Ciotti M; Palamara AT; Marfia GA; Pietropaolo V
    Viruses; 2021 Aug; 13(9):. PubMed ID: 34578264
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Long-term follow-up from the ORATORIO trial of ocrelizumab for primary progressive multiple sclerosis: a post-hoc analysis from the ongoing open-label extension of the randomised, placebo-controlled, phase 3 trial.
    Wolinsky JS; Arnold DL; Brochet B; Hartung HP; Montalban X; Naismith RT; Manfrini M; Overell J; Koendgen H; Sauter A; Bennett I; Hubeaux S; Kappos L; Hauser SL
    Lancet Neurol; 2020 Dec; 19(12):998-1009. PubMed ID: 33129442
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Lessons learned from fatal progressive multifocal leukoencephalopathy in a patient with multiple sclerosis treated with natalizumab.
    Boster AL; Nicholas JA; Topalli I; Kisanuki YY; Pei W; Morgan-Followell B; Kirsch CF; Racke MK; Pitt D
    JAMA Neurol; 2013 Mar; 70(3):398-402. PubMed ID: 23338729
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Association of Progressive Multifocal Leukoencephalopathy Lesion Volume With JC Virus Polymerase Chain Reaction Results in Cerebrospinal Fluid of Natalizumab-Treated Patients With Multiple Sclerosis.
    Wijburg MT; Kleerekooper I; Lissenberg-Witte BI; de Vos M; Warnke C; Uitdehaag BMJ; Barkhof F; Killestein J; Wattjes MP
    JAMA Neurol; 2018 Jul; 75(7):827-833. PubMed ID: 29532061
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Gadolinium enhancement in brain magnetic resonance imaging in progressive multifocal leukoencephalopathy after natalizumab monotherapy: is it really atypical?
    Arnaud FX; Hissene A; Métivier D; Dutasta F; Berets O; N'guema B; A'teriitéhau C; Baccialone J; Potet J
    J Neuroradiol; 2012 Oct; 39(4):267-70. PubMed ID: 22341620
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Evaluating the efficacy and safety of transitioning patients with multiple sclerosis from natalizumab to ocrelizumab (OCTAVE).
    Smoot K; Marginean H; Gervasi-Follmar T; Chen C; Repovic P; Cohan S
    Mult Scler; 2023 Jul; 29(8):956-966. PubMed ID: 37317841
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Switching to ocrelizumab in RRMS patients at risk of PML previously treated with extended interval dosing of natalizumab.
    Mancinelli CR; Scarpazza C; Cordioli C; De Rossi N; Rasia S; Turrini MV; Capra R
    Mult Scler; 2021 Apr; 27(5):790-794. PubMed ID: 32749910
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Diagnosis of asymptomatic natalizumab-associated PML: are we between a rock and a hard place?
    Wattjes MP; Vennegoor A; Mostert J; van Oosten BW; Barkhof F; Killestein J
    J Neurol; 2014 Jun; 261(6):1139-43. PubMed ID: 24705790
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Risk of natalizumab-associated progressive multifocal leukoencephalopathy.
    Bloomgren G; Richman S; Hotermans C; Subramanyam M; Goelz S; Natarajan A; Lee S; Plavina T; Scanlon JV; Sandrock A; Bozic C
    N Engl J Med; 2012 May; 366(20):1870-80. PubMed ID: 22591293
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Update on PML and PML-IRIS occurring in multiple sclerosis patients treated with natalizumab.
    Kleinschmidt-DeMasters BK; Miravalle A; Schowinsky J; Corboy J; Vollmer T
    J Neuropathol Exp Neurol; 2012 Jul; 71(7):604-17. PubMed ID: 22710964
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Natalizumab-associated progressive multifocal leukoencephalopathy in patients with multiple sclerosis: lessons from 28 cases.
    Clifford DB; De Luca A; Simpson DM; Arendt G; Giovannoni G; Nath A
    Lancet Neurol; 2010 Apr; 9(4):438-46. PubMed ID: 20298967
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pembrolizumab Treatment for Progressive Multifocal Leukoencephalopathy.
    Cortese I; Muranski P; Enose-Akahata Y; Ha SK; Smith B; Monaco M; Ryschkewitsch C; Major EO; Ohayon J; Schindler MK; Beck E; Reoma LB; Jacobson S; Reich DS; Nath A
    N Engl J Med; 2019 Apr; 380(17):1597-1605. PubMed ID: 30969503
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Progressive multifocal leukoencephalopathy after natalizumab discontinuation.
    Fine AJ; Sorbello A; Kortepeter C; Scarazzini L
    Ann Neurol; 2014 Jan; 75(1):108-15. PubMed ID: 24242357
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Natalizumab-associated reversible encephalopathy syndrome mimicking progressive multifocal leukoencephalopathy.
    Décard BF; Haghikia A; Tönnes C; Thöne J; Lukas C; Chan A; Gold R
    Mult Scler; 2013 Feb; 19(2):249-51. PubMed ID: 22596228
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pembrolizumab treatment of inflammatory progressive multifocal leukoencephalopathy: a report of two cases.
    Darcy S; Alexander M; McCarthy A; O'Dowd S
    J Neurovirol; 2022 Feb; 28(1):145-150. PubMed ID: 34874539
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cerebrospinal fluid JC virus antibody index for diagnosis of natalizumab-associated progressive multifocal leukoencephalopathy.
    Warnke C; von Geldern G; Markwerth P; Dehmel T; Hoepner R; Gold R; Pawlita M; Kümpfel T; Mäurer M; Stangel M; Wegner F; Hohlfeld R; Straeten V; Limmroth V; Weber T; Hermsen D; Kleinschnitz C; Hartung HP; Wattjes MP; Svenningson A; Major E; Olsson T; Kieseier BC; Adams O
    Ann Neurol; 2014 Dec; 76(6):792-801. PubMed ID: 24729444
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.